Subjective cognitive complaints one year after ceasing adjuvant endocrine therapy for early-stage breast cancer: Findings from the Breast International Group (BIG) 1-98 trial.

被引：0
|
作者：
Phillips, Kelly-Anne
Ribi, Karin
Aldridge, Julie
Thompson, Alastair Mark
Harvey, Vernon J.
Thurlimann, Beat J. K.
Cardoso, Fatima
Pagani, Olivia
Coates, Alan Stuart
Goldhirsch, Aron
Price, Karen N.
Gelber, Richard D.
Bernhard, Juerg
机构：
[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[2] Int Breast Canc Study Grp, Bern, Switzerland
[3] Dana Farber Canc Inst, Int Breast Canc Study Grp, Ctr Stat, Boston, MA 02115 USA
[4] Univ Dundee, Dundee, Scotland
[5] Auckland Hosp, Auckland, New Zealand
[6] Kantonsspital St Gallen, St Gallen, Switzerland
[7] Inst Jules Bordet, B-1000 Brussels, Belgium
[8] Inst Oncol Southern Switzerland, Lugano Viganello, Switzerland
[9] Univ Sydney, Sydney, NSW 2006, Australia
[10] European Inst Oncol, Milan, Italy
[11] IBCSG Stat Ctr, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9022
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer
    K Ribi
    J Aldridge
    K-A Phillips
    A Thompson
    V Harvey
    B Thürlimann
    F Cardoso
    O Pagani
    A S Coates
    A Goldhirsch
    K N Price
    R D Gelber
    J Bernhard
    British Journal of Cancer, 2012, 106 : 1618 - 1625
  • [2] Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer
    Ribi, K.
    Aldridge, J.
    Phillips, K-A
    Thompson, A.
    Harvey, V.
    Thuerlimann, B.
    Cardoso, F.
    Pagani, O.
    Coates, A. S.
    Goldhirsch, A.
    Price, K. N.
    Gelber, R. D.
    Bernhard, J.
    BRITISH JOURNAL OF CANCER, 2012, 106 (10) : 1618 - 1625
  • [3] Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial
    Kelly-Anne Phillips
    Julie Aldridge
    Karin Ribi
    Zhuoxin Sun
    Alastair Thompson
    Vernon Harvey
    Beat Thürlimann
    Fatima Cardoso
    Olivia Pagani
    Alan S. Coates
    Aron Goldhirsch
    Karen N. Price
    Richard D. Gelber
    Jürg Bernhard
    Breast Cancer Research and Treatment, 2011, 126 : 221 - 226
  • [4] Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial
    Phillips, Kelly-Anne
    Aldridge, Julie
    Ribi, Karin
    Sun, Zhuoxin
    Thompson, Alastair
    Harvey, Vernon
    Thuerlimann, Beat
    Cardoso, Fatima
    Pagani, Olivia
    Coates, Alan S.
    Goldhirsch, Aron
    Price, Karen N.
    Gelber, Richard D.
    Bernhard, Juerg
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 126 (01) : 221 - 226
  • [5] Changes in cognitive function in postmenopausal women 1 year after completing adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial.
    Ribi, K.
    Aldridge, J.
    Phillips, K.
    Sun, Z.
    Thompson, A. M.
    Harvey, V. J.
    Thuerlimann, B.
    Cardoso, F.
    Coates, A. S.
    Bernhard, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 Trial
    Ewertz, Marianne
    Gray, Kathryn P.
    Regan, Meredith M.
    Ejlertsen, Bent
    Price, Karen N.
    Thuerlimann, Beat
    Bonnefoi, Herve
    Forbes, John F.
    Paridaens, Robert J.
    Rabaglio, Manuela
    Gelber, Richard D.
    Colleoni, Marco
    Lang, Istvan
    Smith, Ian E.
    Coates, Alan S.
    Goldhirsch, Aron
    Mouridsen, Henning T.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (32) : 3967 - 3975
  • [7] The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer
    Monnier, Alain M.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (05) : 627 - 634
  • [8] Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial
    Ribi, K. E.
    Phillips, K. A.
    Sun, Z.
    Stephens, A.
    Thompson, A.
    Harvey, V.
    Thuerlimann, B.
    Cardoso, F.
    Coates, A. S.
    Bernhard, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial
    Munzone, E.
    Giobbie-Hurder, A.
    Gusterson, B. A.
    Mallon, E.
    Viale, G.
    Thurlimann, B.
    Ejlertsen, B.
    MacGrogan, G.
    Bibeau, F.
    Lelkaitis, G.
    Price, K. N.
    Gelber, R. D.
    Coates, A. S.
    Goldhirsch, A.
    Colleoni, M.
    ANNALS OF ONCOLOGY, 2015, 26 (12) : 2442 - 2449
  • [10] Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial
    Leone, Jose P.
    Cole, Bernard F.
    Regan, Meredith M.
    Thurlimann, Beat
    Coates, Alan S.
    Rabaglio, Manuela
    Giobbie-Hurder, Anita
    Gelber, Richard D.
    Ejlertsen, Bent
    Harvey, Vernon J.
    Neven, Patrick
    Lang, Istvan
    Bonnefoi, Herve
    Wardley, Andrew
    Goldhirsch, Aron
    Di Leo, Angelo
    Colleoni, Marco
    Vaz-Luis, Ines
    Lin, Nancy U.
    CANCER, 2021, 127 (05) : 700 - 708
12345